How to Get Zetia (Ezetimibe) in Rhode Island

What Is Ezetimibe and Why Might a Rhode Island Resident Need It?

Ezetimibe blocks the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the small intestine, reducing dietary and biliary cholesterol absorption by roughly 50 percent. The FDA approved it in 2002 under the brand name Zetia for primary hypercholesterolemia, mixed hyperlipidemia, and homozygous familial hypercholesterolemia. Generic versions became available in 2017, making the drug substantially more affordable.

The American College of Cardiology and American Heart Association 2018 cholesterol guideline states that ezetimibe is a first-line nonstatin agent to add when LDL-C remains above goal on maximally tolerated statin therapy. The full guideline is available via the AHA. For Rhode Island patients who cannot tolerate high-intensity statins due to myalgia, or who need additional LDL lowering on top of rosuvastatin or atorvastatin, ezetimibe is often the next logical step.

Roughly 94 million American adults have total cholesterol above 200 mg/dL, according to CDC surveillance data. Rhode Island's age-adjusted cardiovascular mortality rate is comparable to the national median, making aggressive LDL management clinically relevant across the state.

The key IMPROVE-IT trial (N=18,144) randomized patients with recent acute coronary syndrome to simvastatin 40 mg alone or simvastatin 40 mg plus ezetimibe 10 mg. At seven years, the combination arm achieved a mean LDL-C of 53.7 mg/dL vs. 69.5 mg/dL in the statin-only arm, with a statistically significant reduction in the composite cardiovascular endpoint (32.7% vs. 34.7%; HR 0.936 to 95% CI 0.89 to 0.99, P<0.001). Full IMPROVE-IT results are published in the New England Journal of Medicine.

Who Can Prescribe Zetia in Rhode Island?

Any licensed prescriber in Rhode Island may write for ezetimibe. That includes physicians (MD, DO), nurse practitioners (NP) with a Rhode Island collaborative practice agreement or independent licensure, and physician assistants (PA) practicing under physician supervision. Rhode Island prescriptive authority for APRNs is codified under RIGL Chapter 5-34.

Cardiologists and lipidologists see the highest volume of ezetimibe prescriptions, but primary care physicians and internal medicine physicians write the majority of new scripts in Rhode Island. Endocrinologists commonly prescribe it for patients with type 2 diabetes and elevated cardiovascular risk.

Telehealth prescribing is fully legal in Rhode Island for ezetimibe. The Rhode Island Department of Health permits synchronous audio-visual telehealth visits for new and established patients. Prescribers must maintain a valid Rhode Island license and must conduct a clinically appropriate evaluation before issuing a new prescription. There is no Rhode Island-specific restriction that limits ezetimibe to in-person encounters.

How to Get a Zetia Prescription Through Telehealth in Rhode Island

The fastest path for most Rhode Island residents is a telehealth visit. The typical process has four steps.

Step 1. Schedule a telehealth visit. Platforms licensed to prescribe in Rhode Island include national telehealth services and HealthRX-affiliated providers. Appointments are often available within 24 to 48 hours for lipid management consultations.

Step 2. Upload or complete pre-visit labs. Most telehealth providers require a current fasting lipid panel (within 90 days) and a brief cardiac risk history. If the patient is starting a statin at the same time, liver function tests (ALT, AST) are standard. The ACC/AHA lipid guideline recommends baseline LDL-C measurement before starting any LDL-lowering agent.

Step 3. Attend the video visit. The clinician reviews the lipid panel, calculates 10-year ASCVD risk using the Pooled Cohort Equations, and determines whether ezetimibe monotherapy or combination therapy with a statin is appropriate. The visit typically runs 15 to 20 minutes.

Step 4. Receive and fill the prescription. The prescriber sends an e-prescription directly to a Rhode Island pharmacy or to a mail-order pharmacy licensed to ship to Rhode Island. Same-day pickup at CVS, Walgreens, or Rite Aid locations throughout Providence, Cranston, Warwick, and Woonsocket is available once the e-Rx is transmitted.

A patient who schedules a morning telehealth appointment can reasonably have ezetimibe in hand the same afternoon. That is faster than the average wait for a new in-person cardiology appointment in Rhode Island, which AHRQ data suggests can run four to six weeks.

What Labs Are Needed Before Starting Ezetimibe in Rhode Island?

A fasting lipid panel is the minimum requirement. The panel should include total cholesterol, LDL-C (calculated or direct), HDL-C, and triglycerides. Fasting for nine to twelve hours before the draw improves triglyceride accuracy.

If a statin will be co-prescribed, baseline hepatic function tests are appropriate per FDA labeling for statins. Ezetimibe itself does not require hepatic monitoring in patients with normal baseline liver function, but the FDA Zetia label notes that ezetimibe and statins combined showed hepatic transaminase elevations (>3x ULN) in 1.3 percent of patients vs. 0.4 percent for statin monotherapy.

Creatine kinase (CK) is not routinely required before ezetimibe alone, but a baseline CK may be drawn if the prescriber plans to add a statin and the patient reports a personal or family history of myopathy. The ACC/AHA 2018 guideline recommends baseline CK in patients at elevated myopathy risk before statin initiation.

Follow-up lipid panels are typically ordered four to twelve weeks after starting ezetimibe to confirm LDL response.

Rhode Island Pharmacies That Dispense Ezetimibe

Generic ezetimibe 10 mg tablets are stocked at virtually every retail pharmacy chain in Rhode Island, including:

• CVS Pharmacy (statewide, with locations in Providence, Warwick, Cranston, Pawtucket, and Woonsocket)
• Walgreens (multiple RI locations)
• Rite Aid (RI locations)
• Stop and Shop pharmacy counters
• Independent pharmacies licensed by the Rhode Island Department of Business Regulation

Mail-order pharmacies licensed to ship to Rhode Island include CVS Caremark, Express Scripts, OptumRx, and Costco Pharmacy (online). A 90-day supply via mail order typically costs less per dose than monthly retail fills.

503A compounding pharmacies in Rhode Island are licensed to prepare custom formulations of ezetimibe for patients with documented medical need (for example, a dye-free tablet for patients with specific excipient allergies). The FDA's 503A guidance clarifies that 503A pharmacies compound on a patient-specific prescription basis. Rhode Island's Board of Pharmacy maintains the state compounding pharmacy register.

Generic ezetimibe cash price at major Rhode Island pharmacies ranges from approximately $15 to $40 for a 30-day supply without insurance, based on GoodRx pricing data as of mid-2025. The FDA's Orange Book confirms AB-rated generic ezetimibe from multiple manufacturers, ensuring therapeutic equivalence.

Rhode Island Medicaid (RIte Care) Coverage for Ezetimibe

RIte Care, Rhode Island's Medicaid managed care program, covers generic ezetimibe for hyperlipidemia with prior authorization. The PA criteria generally require documentation of:

1. A diagnosis of hyperlipidemia, mixed dyslipidemia, or familial hypercholesterolemia
2. A trial of at least one preferred statin (typically atorvastatin or simvastatin) at the maximum tolerated dose, or documentation of statin intolerance
3. LDL-C remaining above the guideline-recommended goal after statin optimization

The Centers for Medicare and Medicaid Services PA framework applies to Medicare Part D plans operating in Rhode Island as well. Medicare Part D formularies vary by plan, but most include generic ezetimibe on Tier 1 or Tier 2 after statin step-therapy is documented.

Commercial insurers in Rhode Island (Blue Cross Blue Shield of RI, Tufts Health Plan, United Healthcare, Aetna) typically place generic ezetimibe on Tier 2 or Tier 3 formulary. Step therapy requiring a statin trial first is common. Copays range from $10 to $50 per month depending on the plan tier and whether the member has met their deductible.

If a prior authorization is denied, Rhode Island law provides the right to appeal. The prescriber must submit a letter of medical necessity, the patient's lipid lab results, and documentation of the statin trial. CMS guidance on Part D appeals outlines the timeline: initial determination within 72 hours (standard) or 24 hours (expedited).

What Prior Authorization Documentation Is Required in Rhode Island?

For most Rhode Island commercial and Medicaid plans, the PA packet for ezetimibe needs these five elements.

Diagnosis code. ICD-10 E78.5 (hyperlipidemia, unspecified), E78.00 (pure hypercholesterolemia), or E78.01 (familial hypercholesterolemia) depending on the clinical picture.

Lipid lab values. A dated fasting lipid panel showing LDL-C above the plan's threshold. For ASCVD patients, that is typically LDL-C >70 mg/dL despite statin therapy. For primary prevention high-risk patients, the threshold is often LDL-C >100 mg/dL.

Statin trial documentation. Records showing at least a 4-week trial of a preferred formulary statin at the maximum tolerated dose. If the patient is statin-intolerant, the prescriber must document the adverse effect (myalgia with CK elevation, hepatotoxicity, or confirmed rhabdomyolysis).

ASCVD risk calculation. Many plans now request the 10-year ASCVD risk score. Scores at or above 7.5 percent generally satisfy the high-risk threshold per the ACC/AHA Pooled Cohort Equations.

Letter of medical necessity. A brief clinician statement explaining why ezetimibe is the appropriate next step. Referencing IMPROVE-IT outcomes data and the ACC/AHA 2018 guideline recommendation strengthens the letter.

Telehealth prescribers can complete and submit PA documentation electronically. Rhode Island law does not require an in-person visit to initiate or renew a prior authorization.

Transferring a Zetia Prescription to Rhode Island

Patients relocating to Rhode Island from another state can transfer an existing ezetimibe prescription under the following conditions.

A retail pharmacy transfer is straightforward if the prescription has refills remaining. Federal law and Rhode Island pharmacy regulations allow one transfer of a non-controlled prescription between pharmacies. Chain pharmacies (CVS, Walgreens) can typically process inter-state transfers within the same corporate network same-day.

If the prescription has no refills remaining, the patient needs a new prescription from a Rhode Island-licensed prescriber. A telehealth visit is the fastest way to establish care and receive a new script, often the same day the visit occurs.

Patients moving from another state who are covered by a Rhode Island insurance plan will need their new plan's formulary reviewed. The prescribing physician should confirm that the step-therapy documentation from the previous state is on file and submittable if the new insurer requires a PA.

Out-of-state prescriptions from unlicensed prescribers cannot be filled at Rhode Island pharmacies. The dispensing pharmacist must verify that the prescribing clinician holds a valid license in the state where the prescription was written.

Ezetimibe Efficacy: What Rhode Island Patients Should Expect

Ezetimibe 10 mg once daily typically reduces LDL-C by 13 to 20 percent as monotherapy, according to pooled analysis data available via PubMed. Added to a moderate-intensity statin, the combination produces LDL reductions roughly double what the statin achieves alone.

IMPROVE-IT enrolled 18,144 patients post-acute coronary syndrome and followed them for a median of six years. The ezetimibe plus simvastatin group achieved a 6.4% relative risk reduction in major adverse cardiovascular events compared to simvastatin alone (HR 0.936; P<0.001). The full trial report is in the New England Journal of Medicine. Dr. Christopher Cannon, the IMPROVE-IT lead investigator, stated in the NEJM publication: "These data validate the LDL hypothesis and support the use of combination lipid-lowering therapy in high-risk patients."

For patients with heterozygous familial hypercholesterolemia, ezetimibe combined with a high-intensity statin can reduce LDL-C by 55 to 65 percent. FH-specific guidance from the European Atherosclerosis Society recommends ezetimibe as second-line therapy after maximally tolerated statin.

The drug's tolerability profile is favorable. In IMPROVE-IT, adverse event rates between ezetimibe-statin and statin-alone groups were similar. Myopathy occurred in <0.1% of patients in each arm. The FDA Zetia label lists the most common adverse reactions as upper respiratory infection (4.3%), diarrhea (4.1%), arthralgia (3.0%), sinusitis (2.8%), and pain in extremity (2.7%).

LDL reduction becomes measurable within two weeks of starting ezetimibe, with steady-state effect by four to six weeks. A follow-up lipid panel at the six-week mark is the standard clinical checkpoint. The ACC/AHA guideline recommends reassessing adherence and response at four to twelve weeks.

Ezetimibe Dosing and Drug Interactions Relevant to Rhode Island Prescribers

The approved adult dose is ezetimibe 10 mg once daily, taken with or without food, at any time of day. FDA prescribing information confirms no food-effect modification.

Bile acid sequestrants (cholestyramine, colesevelam) reduce ezetimibe absorption by approximately 55 percent. Rhode Island prescribers combining these agents should instruct patients to take ezetimibe at least two hours before or four hours after the sequestrant dose. This interaction is documented in the NLM Drug Interaction database.

Cyclosporine significantly increases ezetimibe plasma levels (by roughly 3.4-fold). Patients in Rhode Island transplant programs at Rhode Island Hospital or Miriam Hospital who are on cyclosporine require closer monitoring and dose consideration. The FDA label addresses this interaction specifically.

Fibrates (fenofibrate, gemfibrozil) may increase ezetimibe glucuronide concentrations. Gemfibrozil co-administration is listed as a caution in FDA labeling given the added risk of cholelithiasis when both drugs are present.

No dose adjustment is needed for mild hepatic impairment. Ezetimibe is not recommended in patients with moderate or severe hepatic impairment due to unknown pharmacokinetics. Prescribing information from FDA is the governing reference.

Cost Reduction Strategies for Rhode Island Patients

Generic ezetimibe is the most direct cost reduction. Brand Zetia carries a list price near $300 per month; the AB-rated generic costs $15 to $40 at most Rhode Island pharmacies with a coupon.

GoodRx and RxSaver coupons are accepted at CVS, Walgreens, and Rite Aid in Rhode Island and typically yield the lowest out-of-pocket price for uninsured patients. The FDA confirms generic bioequivalence, so therapeutic outcomes are identical.

Merck's patient assistance program for brand Zetia (Merck Patient Assistance) covers patients below 400 percent of the federal poverty level who lack prescription coverage. Application is submitted by the prescribing clinician. Program details are maintained at NeedyMeds, a resource indexed through NIH.

Rhode Island's RIte Care Medicaid covers generic ezetimibe post-PA approval at no copay for most members. Medicare Part D Low-Income Subsidy (Extra Help) recipients in Rhode Island pay $0 to $4.00 per fill for Tier 1 generics at participating pharmacies.